ANDA 218606, held by Acertis Pharms. Metolazone.
As of Nov 16, 2026, ANDA 218606 (Metolazone), held by Acertis Pharms, was first approved by FDA on Apr 17, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2024 | Original application | Approved | None posted |
| Metolazone2.5MG · tablet;oral | Metolazone | Rx |
| Metolazone5MG · tablet;oral | Metolazone | Rx |
| Metolazone10MG · tablet;oral | Metolazone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters